MedTrace Logo

Chemo-Radiotherapy Boost Treatment Guided by Perfusion MRI on Hypoxic Zones in Head and Neck Cancer

NCT06880289 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2025-03-17

No results posted yet for this study

Summary

To assess and localize hypoxic tumor subregions both at baseline and during the second week of radiotherapy. And to hypothesize that an intensified IMRT regimen may ensure higher local response rates compared to the standard IMRT approach.

Conditions

  • Squamous Cell Tumors of the Head and Neck

Interventions

DRUG

Cisplatin IV on days 1, 22, 43, at a dose of 100 mg/m2

Chemoradiotherapy will be performed from day 1 to day 49 regardless of the arm.

Sponsors & Collaborators

  • Regina Elena Cancer Institute

    lead OTHER

Principal Investigators

  • Giuseppe Sanguineti, Doctor · IRCCS National Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-16
Primary Completion
2024-07-31
Completion
2027-07-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06880289 on ClinicalTrials.gov